Calithera Biosciences, Inc. · OTC:CALA
Calithera Biosciences — ASCO 2021
16 slides from Calithera Biosciences's conference presentation, July 2021
Slide 1: CANTATA: Primary Analysis of Telaglenastat + Cabozantinib vs. Placebo + Cabozantinib in RCC
<br />Abstract #4501<br /><br />CANTATA: Primary Analysis of a Global, Randomized, Placebo-Controlled, Double-Blind Trial of Telaglenastat (CB-839) + Cabozantinib vs. Placebo + Cabozantinib in Patients With Advanced/Metastatic Renal Cell Carcinoma that Progressed on Immune Checkpoint Inhibitor or An
Slide 2: Altered Tumor Metabolism in Tumor Cells
Altered Tumor Metabolism in Tumor Cells Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 3: Rationale for Telaglenastat + Cabozantinib in RCC
Rationale for Telaglenastat + Cabozantinib in RCC Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 4: CANTATA Study Design
CANTATA Study Design Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 5: Statistical Plan
Statistical Plan Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 6: Demographics and Patient Characteristics
Demographics and Patient Characteristics Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 7: Efficacy (IRC-Assessed)
Efficacy (IRC-Assessed) Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 8: IRC-Assessed Progression-Free Survival
IRC-Assessed Progression-Free Survival Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 9: PFS (IRC) Subgroup Analysis
PFS (IRC) Subgroup Analysis Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 10: PFS (IRC): Subgroup of Patients With Prior ICI
PFS (IRC): Subgroup of Patients With Prior ICI Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 11: Content of this presentation is the property of the author, licensed by ASCO. Permission
Slide 11 Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 12: Treatment-Emergent Adverse Events
Treatment-Emergent Adverse Events Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 13: Safety Summary
Safety Summary Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 14: Conclusions
Conclusions Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 15: Perspectives
Perspectives Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 16: Acknowledgements
Acknowledgements Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.